The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders

Pharmacotherapy
March 2018
https://pubmed.ncbi.nlm.nih.gov/29377216/

The multifaceted role of astrocytes in regulating myelination

Exp Neurol.
September 2016
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019113/

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis

Exp Biol Med (Maywood)
February 2018
https://pubmed.ncbi.nlm.nih.gov/29307283/

McLaughlin leads research on identifying minimally invasive biomarkers for MS

Penn State News
10 April 2018
https://news.psu.edu/story/515260/2018/04/10/research/mclaughlin-leads-research-identifying-minimally-invasive-biomarkers

Low-dose Naltrexone Changes Levels of Inflammatory Proteins in MS, Study Shows

MS News Today
20 February 2018
https://multiplesclerosisnewstoday.com/2018/02/20/low-dose-naltrexone-changes-levels-inflammatory-proteins-in-ms/

Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy

Int Immunopharmacol
August 2018
https://pubmed.ncbi.nlm.nih.gov/29885638/

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

Cureus
10 July 2018
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126779/

Low-dose naltrexone: A possible safe effective treatment for autoimmune disease and cancer

Anti-Aging Therapeutics, Volume 12, Chapter 3
January 2009
https://books.google.co.il/books?id=BSfzEE0tT9cC&lpg=PR7&dq=low%20dose%20naltrexone&pg=PR7#v=onepage&q=low%20dose%20naltrexone&f=false

The Long Term Suppression of Experimental Autoimmune Encephalomyelitis by the Opioid Growth Factor and Low Dose Naltrexone

The FASEB Journal
01 April 2011
https://doi.org/10.1096/fasebj.25.1_supplement.677.6 

Intermittent blockade of OGFr and treatment of autoimmune disorders

Exp Biol Med (Maywood)
December 2018
https://pubmed.ncbi.nlm.nih.gov/30541348/